Literature DB >> 6614646

Human alveolar macrophage support of lymphocyte responses to mitogens and antigens. Analysis and comparison with autologous peripheral-blood-derived monocytes and macrophages.

D B Ettensohn, N J Roberts.   

Abstract

Observations from animal studies and investigations using human peripheral-blood-derived macrophages may not be representative of human alveolar macrophage functions. Thus, we extensively examined and compared accessory cell functions of autologous human alveolar macrophages and peripheral-blood-derived monocytes and macrophages obtained from healthy, nonsmoking volunteer subjects. The alveolar and peripheral-blood-derived cells differed in ability to enhance mitogen- and antigen-stimulated transformation responses of purified autologous lymphocytes. Peripheral-blood-derived cells supported greater lymphocyte responses to optimal concentrations of several mitogens, but alveolar macrophages supported much greater responses to suboptimal concentrations of the mitogen phytohemagglutinin. Peripheral-blood-derived macrophages supported, but alveolar macrophages did not support, lymphocyte responses to streptococcal and influenza virus antigens. Such relative accessory cell functions of the different macrophages and monocytes were not due to different kinetics of response, nor were they due to differences in the proportion of macrophages required to support the lymphocyte responses. These data indicate that human alveolar macrophages have functional characteristics different from autologous peripheral-blood-derived monocytes and macrophages. Such differences may be important in both pulmonary immune homeostasis and in the pathogenesis of pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6614646     DOI: 10.1164/arrd.1983.128.3.516

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  21 in total

1.  Life in the allogeneic environment after lung transplantation.

Authors:  I Paradis; H Rabinowich; A Zeevi; S Yousem; B Noyes; R Hoffman; B Griffith; J Dauber
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Immunosuppression by pulmonary surfactant: mechanisms of action.

Authors:  M L Wilsher; D J Parker; P L Haslam
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

3.  Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease.

Authors:  D A Campbell; L W Poulter; R M Du Bois
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

4.  Bronchoalveolar lavage in talc induced lung disease.

Authors:  A A Redondo; D B Ettensohn; M Khan; N Kessimian
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

Review 5.  Down-regulation of immune responses in the lower respiratory tract: the role of alveolar macrophages.

Authors:  P G Holt
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

6.  Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Thorax       Date:  1988-05       Impact factor: 9.139

7.  Immunomodulatory effects of pulmonary surfactant on natural killer cell and antibody-dependent cytotoxicity.

Authors:  M L Wilsher; D A Hughes; P L Haslam
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

8.  An immunohistochemical study on phenotypic heterogeneity of human pulmonary vascular endothelial cells.

Authors:  M Yamamoto; K Shimokata; H Nagura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

9.  Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages.

Authors:  T Kawabe; K I Isobe; Y Hasegawa; I Nakashima; K Shimokata
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

10.  Human Alveolar Macrophages May Not Be Susceptible to Direct Infection by a Human Influenza Virus.

Authors:  David B Ettensohn; Mark W Frampton; Joan E Nichols; Norbert J Roberts
Journal:  J Infect Dis       Date:  2016-09-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.